Finance Watch: TRexBio Raises $84m To Pursue Proof Of Concept In Inflammatory Diseases

Private Company Edition: TRexBio’s series B venture capital round will fund initial clinical trials for TRB-061, a TNFR2 agonist. And in addition to mega-rounds from Trace, Alentis and Metsera, Evommune and Axonis raised $115m each, while Elektrofi completed a $112.5m series C.